A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) - Trial NCT06331598
Access comprehensive clinical trial information for NCT06331598 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hoffmann-La Roche and is currently Recruiting. The study focuses on Solid Tumors. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hoffmann-La Roche
Timeline & Enrollment
Phase 2
Jul 30, 2024
Sep 20, 2029
Primary Outcome
Disease Free Survival (DFS) Rate at 24 Months
Summary
This study is being conducted to evaluate efficacy parameters (disease free survival [DFS]
 and overall survival [OS]) of atezolizumab and atezolizumab in combination with tiragolumab
 in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in
 participants with intermediate-high risk of recurrence.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06331598
Non-Device Trial